LIVE SESSION BRIEF Biotechnology $670M Cap Quant: HOLD

Arvinas, Inc (ARVN) — Live Session & Technical Brief

Updated Nov 16, 2026 2:50 PM ET · Prev Close $6.82

Pro Workspace
Last Session Price
$6.74 -1.17%
-$0.08 vs $6.82 prior close
Intraday Range
$6.70 – $6.89
Open $6.83
Relative Volume
0.96x Avg
884,721 sh
52-Week Range
$6.33 – $14.51
Benchmark Alpha
+0.81% vs SPY
+1.46% vs QQQ
20-Session Trend -12.0%

Session Regime & Catalyst Assessment

64% Signal Conviction
TECHNICAL 64% Driver Weight

Controlled Session Consolidation (-1.17%) in Biotechnology

Arvinas, Inc (ARVN) is trading within a tight intraday band at $6.74 (-1.17%, 0.96x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ARVN is outperforming the S&P 500 by +0.81%. 14-day RSI stands at 41.7, keeping momentum in a bearish regime.

NEWS 70% Weight
Arvinas to Present at Jefferies Global Healthcare Conference

New Haven, Conn., Nov. 11, 2026 Globe Newswire -- Arvinas, Inc. Nasdaq ARVN , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management wi

TECHNICAL 68% Weight
Moving Average Structure: Bearish Alignment

Price ($6.74) trades relative to 20-day SMA ($7.22) and 50-day SMA ($7.57).

Volume Confirmation
MODERATE VOLUME (0.96x) Normal
Institutional participation confirms directional price action.
Composite Catalyst Confidence 64%
Cross-checked across volume tape, benchmark alpha, options flow, and news.

Market & Sector Relative Strength

ARVN outperforming the S&P 500 by +0.81%
ARVN Session
-1.17%
$6.74
S&P 500 (SPY)
-1.98%
$739.44
Nasdaq 100 (QQQ)
-2.63%
$661.99
Healthcare (XLV)
-0.32%
$188.25
Alpha vs SPY: +0.81% Alpha vs QQQ: +1.46% Alpha vs XLV: -0.85%

Recent ARVN Catalyst Headlines

Verified Wire
Arvinas to Present at Jefferies Global Healthcare Conference

New Haven, Conn., Nov. 11, 2026 Globe Newswire -- Arvinas, Inc. Nasdaq ARVN , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management wi

Yahoo Finance · Nov 11, 2026
What Arvinas Bears Saw Before The Fall

Arvinas shocked the market with its latest quarterly filing, reporting Q2 2026 revenue of US 249.7 million and net income of US 169.4 million, a sharp shift from losses a year earlier, yet the share chart tells a differe

Yahoo Finance · Nov 04, 2026

1–3 Day Expected Range & Key Level

54% Follow-Through
Lower Bound
$6.51
Short-term support band
Upper Bound
$6.97
Short-term resistance band
Key Inflection Level
$7.22 (20-day SMA resistance)

Monitor volume expansion above 1.5x RVOL around $7.22 (20-day SMA resistance) for directional breakout confirmation.

Technical Regime (ARVN)

BEARISH MA TREND
RSI (14)
41.7
Bearish
20-Day SMA
$7.22
Below 20d
50-Day SMA
$7.57
Below 50d
MACD Signal
Bearish
MACD -0.24
ADX (14)
22.3
Moderate trend
10d Momentum
-0.74
Soft 10-day momentum

Retail & Crowd Sentiment

Bullish
24h Messages
0
7d avg 0.0
Bullish / Bearish
0.0% / 0.0%
None buzz
Crowd Discussion Digest

Arvinas is presenting preliminary clinical data from the Phase 1 study of Arv-393 (zaloblideg), an oral Protac BCL6 degrader, at the 2026 American Society of Hematology (ASH) Annual Meeting. The data will include safety, pharmacokinetics, and pharmacodynamics from all patients, with preliminary efficacy from patients with T-cell lymphomas.

Reddit communities: 1 comment (Bullish)

About Arvinas, Inc

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (Protac), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The …

Sector
Healthcare
Market Cap
$670M
Forward P/E
17.7x
Employees
430

Get Instant ARVN Catalyst Alerts

Receive an email alert when ARVN triggers an unusual volume breakout, options sweep, or rating shift.

Other Liquid Stocks Moving Today

All Today's Movers

ARVN Session & Catalyst FAQ

Why is ARVN stock trading near flat today?

Arvinas, Inc (ARVN) is trading within a tight intraday band at $6.74 (-1.17%, 0.96x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ARVN is outperforming the S&P 500 by +0.81%. 14-day RSI stands at 41.7, keeping momentum in a bearish regime.

Is ARVN stock a buy or sell right now?

Today's session carries a 64% catalyst conviction score on 0.96x relative volume (moderate participation). Our multi-factor model currently rates ARVN as HOLD. Review full valuation, quality, and timing signals on the ARVN Buy or Sell Decision Brief →

What is ARVN's intrinsic value and expected trading range?

At $6.74, ARVN's modeled 1-to-3 session range is $6.51 – $6.97, with a key inflection level at $7.22 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the ARVN Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →

What do RSI and moving averages signal for ARVN?

RSI at 41.7 reflects soft below-midline momentum. ARVN trades at $6.74 relative to its 20-day SMA ($7.22) and 50-day SMA ($7.57), reflecting a bearish moving-average structure.

Tradestie Flagship Research & Market Hubs